PYC Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PYC Therapeutics Limited
Phylogica Surges On Early CPP Cancer Results
Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.
BioNotebook: One deal ends for Vanda, Novartis; five new agreements begin
Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.
Vaccines Chess Game Continues With Baxter Sale To Pfizer
Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.
Deals Shaping the Medical Industry (2/2012)
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Phylogica Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.